BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-α in chronic myeloid leukemia patients

Blood

Volumn 94, Issue 7, 1999, Pages 2200-2207

  Pane, Fabrizio ^a   Mostarda, Ilaria ^a   Selleri, Carmine ^a   Salzano, Rossella ^a   Raiola, Anna Maria ^a   Luciano, Luigia ^a   Saglio, Giuseppe ^a   Rotoli, Bruno ^a   Salvatore, Francesco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA;

ARTICLE; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REMISSION;

EID: 0033214185     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2200.419a33_2200_2207     Document Type: Article

References (47)

1. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:9399, 1984
2. bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
3. Strife A, Lambek C, Wisniewski D, Wachter M, Gulati SC, Clarkson BD: Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res 48:1035, 1988
4. Marley SB, Lewis JL, Goldman JM, Gordon MY: Abnormal kinetics of colony formation by erythroid burst-forming units in chronic myeloid leukemia. Br J Haematol 93:878, 1996
5. Bedi A, Zembauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR/ABL in chronic myeloid leukemia. Blood 83:2038, 1994
6. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: bcr/abl-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
7. McGahon A, Brown DG, Martin SJ, Amarante-Mendes GP, Cotter TG, Cohen GM, Green DR: Downregulation of bcr/abl in K562 cells restores susceptibility to apoptosis: Characterization of apoptotic death. Cell Death Differ 4:95, 1997
8. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL: Differential complementation of bcr/abl point mutation with c-myc. Science 264:424, 1994
9. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for Ras in the transformation of fibroblasts and hemopoietic cells by the Bcr/Abl oncogene. J Exp Med 181:307, 1995
10. Goldman JM: Chronic myeloid leukemia. Curr Opin Hematol 4:277, 1997
11. Petska S, Langer JA, Zoon KC, Samuel CE: Interferons and their action. Annu Rev Biochem 56:727, 1987
12. Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzkock R: Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res 52:1087, 1992
13. Nicholson NL, Talpaz M, Nicholson GL: Interferon-α directly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complex: Correlation with IFN-α treatment outcome in patients with chronic myelogenous leukemia. Gene 159:105, 1995
14. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Test JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic phase myelogenous leukemia: Effect on remission duration and survival. Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
15. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Long-term follow-up of the Italian trial of Interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541, 1998
16. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069, 1996
17. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254, 1995
18. Allan NC, Richards SM, Sheperd PCA: UK Medical Research Council randomised multicentre trial of interferon-α1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
19. Upadhyaya G, Guba S, Sih S, Feinberg A, Talpaz M, Kantarjian H, Deisseroth A, Emerson S: Interferon alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 88:2131, 1991
20. Bhatia R, Wayner EA, McGlave PB, Verfaule CM: Interferon-α restores normal adhesion of chronic myelogenous leukemia hemopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J Clin Invest 94:384, 1994
21. Dowding C, Gordon M, Guo A-P, Maison D, Osterholz J, Siczkowski M, Goldman J: Potential mechanisms of action of interferon-α in CML. Leuk Lymphoma 11:185, 1993
22. Selleri C, Sato T, Del Vecchio L, Luciano L, Barret AJ, Rotoli B, Young NS, Maciejewski JP: Involvment of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood 89:957, 1997
23. Rizzoli V, Savoldo B, Regazzi E, Garau D, Sammarelli G, Mangoni L, Carlo Stella C: Chronic myelogenous leukemia CD34+ marrow cells lacking CD95 expression are enriched for BCR/ABL negative primitive and committed progenitors. Bone Marrow Transplant 19:30, 1997 (abstr, suppl 1)
24. Miyamura K, Iijima N, Itou T, Tanimoto M, Saito H: Functional expression of Fas receptor on the progenitor cells of chronic myelogenous leukemia. Induction by interferon-γ and ubenimex. Blood 88:232, 1996 (abstr, suppl 1)
25. Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I, Salvatore F, Rotoli B: Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood 92:981, 1998
26. Yanagisawa K, Yamauchi H, Kaneko M, Khono H, Hasegawa H, Fujita S: Suppression of cell proliferation and of the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-α. Blood 91:641, 1998
27. Chomczynski P, Sacchi N: Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
28. Pane F, Frigeri F, Camera A, Sindona M, Brighel F, Martinelli V, Luciano L, Selleri C, Del Vecchio L, Rotoli B, Salvatore F: Complete phenotypic and genotypic lineage switch in a Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 10:741, 1996
29. Pane F, Salera A, Mostarda I, Salvatore F, Sacchetti L: Estimation of extremely low amounts of single mRNAs by quantitative noncompetitive RT-PCR assay in biological specimen from normal and neoplastic cells. Anal Biochem 225:362, 1995
30. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, De Micheli D, Parziale A, Martinelli G, Salvatore F: Consistent amounts of acute leukemia-associated P190 bcr/abl transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 87:1075, 1996
31. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
32. Grossman A, Silver RT, Szatrowski TP, Gutfriend A, Verma RS, Benn PA: Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 5:540, 1991
33. Negrini M, Tallarico A, Pazzi I, Castagnoli A, Cuneo A, Castoldi GL: A new chromosomal breakpoint in Ph-positive, bcr-negative chronic myelogenous leukemia. Cancer Genet Cytogenet 61:11, 1992
34. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU: Therapy of chronic myelogenous leukemia by recombinant interferon-γ. Blood 70:943, 1987
35. Russo D, Zuffa E, Fanin R: Treatment of chronic myeloid leukemia by gamma interferon. Blut 59:15, 1989
36. Kloke O, May D, Wandl U, Becher R, Opalka B, Beer U, Niederle N: Treatment of chronic myelogenous leukemia with interferons alpha and gamma. Blut 61:45, 1990
37. Filmus J, Buick RN: Relationship of c-myc expression to differentiation and proliferation of HL60 cells. Cancer Res 45:822, 1985
38. Tonini GP, Radzioch D, Gronberg A, Clayton M, Blasi E, Benetton G, Varesio L: Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human cell line K562. Cancer Res 47:4544, 1987
39. Eisbruch A, Blick M, Evinger-Hodges MJ, Beran M, Andersson B, Gutterman JU, Kurzrock R: Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer 62:1171, 1988
40. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R: Subcellular localization of Bcr, Ab1, and Bcr-Abl proteins in normal and luekemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92:1925, 1993
41. BCR/ABL.Oncogene 11:1149, 1995
42. BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-CBL. Exp Hematol 24:310, 1996
43. BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12:839, 1996
44. Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L: PI3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 88:1542, 1996
45. Rodorf-Nikolic T, Van Horn DJ, Chen D, White MF, Backer JM: Regulation of phosphatidylinositol-3′ kinase by tyrosyl phosphoproteins. J Biol Chem 270:3662, 1995
46. Gordon MY, Marley SB, Lewis JL, Davidson RJ, Nguyen DX, Grand FH, Amos TAS, Goldman JM: Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 102:710, 1998
47. Cornelissen JJ, Ploemacher RE, Wognum BW, Borsboom A, Kluin-Nelemans HC, Hagemeijer A, Löwemberg B: An in vitro model for cytogenetic conversion in CML. Interferon-α preferentially inhibits the outgrowth of malignant stem cells preserved in long-term cultures. J Clin Invest 102:976, 1998